ClinicalTrials.Veeva

Menu

Multiparametric Imaging for Analysis of MVNT (Multinodular and Vacuolating Neuronal Tumor) (MIAM)

F

Fondation Ophtalmologique Adolphe de Rothschild

Status

Completed

Conditions

Benign Neuronal Desease

Treatments

Device: cerebral MRI

Study type

Observational

Funder types

NETWORK

Identifiers

NCT04103190
ALR_2019_4

Details and patient eligibility

About

Differential diagnoses of MVNT include DNT (dysembryoplastic neuroepithelial tumor), low-grade gliomas, cortical dysplasias or even hamartomas.

Full description

Differential diagnoses of MVNT include DNT (dysembryoplastic neuroepithelial tumor), low-grade gliomas, cortical dysplasias or even hamartomas.

However, in order to avoid an invasive surgical procedure to remove the lesion, a certain diagnosis of its benignity is essential. The contribution of advanced techniques in MRI, such as spectroscopy in the characterization of these lesions, has not yet been studied today

Enrollment

71 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient over 18 years old
  • Suspicion of MVNT on an MRI: it is considered that it will be necessary at least the 2 major criteria associated with at least 1 minor criterion to enter the definition of suspicion of MVNT:

Major criteria:

  • Multinodular aspect in cluster
  • High FLAIR hypersignal / T2

Minor criteria:

  • Absence of mass effect

  • Hyposignal T1

  • Center of the lesion in hypsignal FLAIR or T1 hypersignal

    • Affiliate or beneficiary of a Social Security scheme
    • Having received informed information about the study and consenting to participate in the study

Exclusion criteria

  • Patient benefiting from a legal protection measure
  • Pregnant or lactating woman
  • Contraindication to MRI

Trial contacts and locations

7

Loading...

Central trial contact

Laurence Salomon, MD PhD; Augustin Lecler, MD PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems